litlas
Log inCreate account

John A. Glaspy

Active 1986–2025

134
Papers
34,578
Citations
89
h-index
132
i10-index

Citations

Citations per year for John A. Glaspy1971: 1 citations1986: 1 citations1987: 1 citations1988: 1 citations1989: 3 citations1990: 2 citations1991: 14 citations1992: 19 citations1993: 14 citations1994: 16 citations1995: 20 citations1996: 40 citations1997: 49 citations1998: 78 citations1999: 103 citations2000: 160 citations2001: 186 citations2002: 158 citations2003: 189 citations2004: 187 citations2005: 178 citations2006: 154 citations2007: 163 citations2008: 173 citations2009: 143 citations2010: 192 citations2011: 168 citations2012: 243 citations2013: 225 citations2014: 261 citations2015: 397 citations2016: 472 citations2017: 464 citations2018: 529 citations2019: 1,191 citations2020: 1,321 citations2021: 1,161 citations2022: 922 citations2023: 601 citations2024: 830 citations2025: 336 citations2026: 10 citations1972–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,890 citing papers, 29.7% of this breakdownChina: 1,696 citing papers, 10.3% of this breakdownGermany: 921 citing papers, 5.6% of this breakdownUnited Kingdom: 900 citing papers, 5.5% of this breakdownItaly: 782 citing papers, 4.8% of this breakdownFrance: 702 citing papers, 4.3% of this breakdownCanada: 532 citing papers, 3.2% of this breakdownAustralia: 513 citing papers, 3.1% of this breakdownJapan: 494 citing papers, 3% of this breakdownNetherlands: 477 citing papers, 2.9% of this breakdownSwitzerland: 474 citing papers, 2.9% of this breakdownSpain: 468 citing papers, 2.8% of this breakdown
0%29.7%Other 21.9%

Institutions

Fields

  • Medicine63.1%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology11.1%
  • Nursing1.5%
  • Engineering1%
  • Neuroscience0.5%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers11.5%
  • Immunotherapy and Immune Responses7.8%
  • CAR-T cell therapy research5.6%
  • Immune Cell Function and Interaction3.3%
  • HER2/EGFR in Cancer Research2.5%
  • Melanoma and MAPK Pathways2.2%
  • Other67.1%

Coauthors

All papers

Open in search
  1. PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Authors: Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma Taylor, Lídia Robert, Bartosz Chmielowski, Marko Spasić, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio Gutiérrez, Tristan Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan Emerson, Harlan Robins, Robert H. Pierce, David Elashoff, Caroline Robert, Antoni Ribas - Nature 2014 cited by 6,699

  2. Adjuvant Trastuzumab in HER2-Positive Breast Cancer

    Authors: Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown - New England Journal of Medicine 2011 cited by 2,775

  3. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Authors: Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe, Theodore F. Logan, Axel Hauschild, Célèste Lebbé, Lisa Chen, Jaeyeon Kim, Jennifer Gansert, Robert H.I. Andtbacka, Howard L. Kaufman - Journal of Clinical Oncology 2017 cited by 617

  4. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

    Authors: Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe, Theodore F. Logan, Axel Hauschild, Célèste Lebbé, Harshada Joshi, Wendy Snyder, Janice M. Mehnert - Journal for ImmunoTherapy of Cancer 2023 cited by 89

  5. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

    Authors: Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo - Cancer Discovery 2013 cited by 986

  6. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

    Authors: Robert E. Coleman, Dianne M. Finkelstein, Carlos H. Barrios, Miguel Martín, Hiroji Iwata, Roberto Hegg, John A. Glaspy, Álvaro Montaño Periáñez, Katia Tonkin, Ines Deleu, Joohyuk Sohn, John Crown, Suzette Delaloge, Tian Dai, Ying Zhou, Danielle Jandial, Arlene Chan - The Lancet Oncology 2019 cited by 257

  7. Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer

    Authors: Silvia C. Formenti, Percy Lee, Sylvia Adams, Judith D. Goldberg, Xiaochun Li, Mike W. Xie, Josephine A. Ratikan, Carol Felix, Lin Hwang, Kym F. Faull, James Sayre, Sara A. Hurvitz, John A. Glaspy, Begoña Comı́n-Anduix, Sandra Demaria, Dörthe Schaue, William H. McBride - Clinical Cancer Research 2018 cited by 249

  8. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Authors: Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy - Journal of Clinical Oncology 2011 cited by 1,061

  9. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

    Authors: Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg - Cancer Discovery 2017 cited by 383

  10. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

    Authors: Matti Aapro, Yves Béguin, Carsten Bokemeyer, Mario Dicato, Pere Gascón, John A. Glaspy, Axel Hofmann, Hartmut Link, T. Littlewood, Heinz Ludwig, Anders Österborg, P. Pronzato, Valeria Santini, D. Schrijvers, R. Stauder, Kim Jordan, Jørn Herrstedt - Annals of Oncology 2017 cited by 277

  11. PD-1 Blockade Expands Intratumoral Memory T Cells

    Authors: Antoni Ribas, Daniel Sanghoon Shin, Jesse M. Zaretsky, Juliet Frederiksen, Andrew Cornish, Earl Avramis, Elizabeth Seja, Christine Kivork, Janet Siebert, Paula Kaplan‐Lefko, Xiaoyan Wang, Bartosz Chmielowski, John A. Glaspy, Paul C. Tumeh, Thinle Chodon, Dana Pe’er, Begoña Comı́n-Anduix - Cancer Immunology Research 2016 cited by 410

  12. Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Authors: Neil Senzer, Howard L. Kaufman, Thomas Amatruda, Mike Nemunaitis, Tony Reid, Gregory A. Daniels, René González, John A. Glaspy, Eric D. Whitman, Kevin J. Harrington, Howard Goldsweig, Tracey Marshall, Colin Love, Robert S. Coffin, John Nemunaitis - Journal of Clinical Oncology 2009 cited by 615

  13. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

    Authors: Hope S. Rugo, Lasika Seneviratne, J. Thaddeus Beck, John A. Glaspy, Julio A. Peguero, Timothy Pluard, Navneet K. Dhillon, Leon C. Hwang, Chaitali Nangia, Ingrid A. Mayer, Timothy F. Meiller, Mark S. Chambers, Robert Sweetman, John Sabo, Jennifer K. Litton - The Lancet Oncology 2017 cited by 225

  14. Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Authors: Martina S.J. McDermott, Neil A. O’Brien, Benjamin Hoffstrom, KeWei Gong, Ming Lu, Jun Zhang, Tong Luo, Min Liang, Weiping Jia, Jenny J. Hong, Kevin Chau, Simon Davenport, Bin Xie, Michael F. Press, Richard Panayiotou, Abram Handly‐Santana, Joan S. Brugge, Leonard Presta, John A. Glaspy, Dennis J. Slamon - Clinical Cancer Research 2023 cited by 53

  15. Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

    Authors: Thinle Chodon, Begoña Comı́n-Anduix, Bartosz Chmielowski, Richard C. Koya, Zhongqi Wu, Martin Auerbach, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Tara A. McCannel, Akira Ishiyama, Johannes Czernin, Caius G. Radu, Xiaoyan Wang, David W. Gjertson, Alistair J. Cochran, Kenneth Cornetta, Deborah Jean Lee Wong, Paula Kaplan‐Lefko, Omid Hamid, Wolfram E. Samlowski, Peter A. Cohen, Gregory A. Daniels, Bijay Mukherji, Lili Yang, Jerome A. Zack, Donald B. Kohn, James R. Heath, John A. Glaspy, Owen N. Witte, David Baltimore, James S. Economou, Antoni Ribas - Clinical Cancer Research 2014 cited by 253

  16. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

    Authors: Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil I. Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine I. Rizzo, Kim Margolin - Neuro-Oncology 2021 cited by 125

  17. Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion

    Authors: Dilprit Bagga, Ling Wang, Robin Farias‐Eisner, John A. Glaspy, Srinivasa T. Reddy - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 630

  18. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer

    Authors: Vincent J. Picozzi, Adnan Alseidi, Jordan Winter, Michael J. Pishvaian, Kabir Mody, John A. Glaspy, Timothy Larson, Marc Matrana, Mairead Carney, Seth Porter, Elias Kouchakji, Flavio G. Rocha, Ewa Carrier - ESMO Open 2020 cited by 74

  19. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

    Authors: Ralph V. Boccia, John A. Glaspy, Jeffrey Crawford, Matti Aapro - The Oncologist 2022 cited by 135

  20. Thrombocytopenia caused by the development of antibodies to thrombopoietin

    Authors: Junzhi Li, Chun Yang, Yuping Xia, Amy M. Bertino, John A. Glaspy, Michael T. Roberts, David J. Kuter - Blood 2001 cited by 684

  21. Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer

    Authors: David Miles, Henri Roché, Miguel Martín, Timothy Perren, David Cameron, John A. Glaspy, David Dodwell, Joanne L. Parker, José Mayordomo, A. Trés, James L. Murray, Nuhad K. Ibrahim, the Theratope® Study Group - The Oncologist 2011 cited by 253

  22. A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides

    Authors: Lisa H. Butterfield, Antoni Ribas, Vivian B. Dissette, Yo Han Lee, Jin Q. Yang, Pilar de la Rocha, Sonia Duran, Jackie Hernandez, Elisabeth Seja, Douglas M. Potter, William H. McBride, Richard Finn, John A. Glaspy, James S. Economou - Clinical Cancer Research 2006 cited by 230

  23. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

    Authors: Elizabeth A. Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John H. Baird, Rita Cool, Shira Dinner, Mark B. Geyer, John A. Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel J. Landsburg, Gary H. Lyman, Anjlee Mahajan, Ryan Miller, Victoria Nachar, Seema Patel, Shiven B. Patel, Lia Perez, Adam Poust, Fauzia Riaz, Rachel Rosovsky, Hope S. Rugo, Shayna Simon, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Ryan A. Berardi, Lenora A. Pluchino - Journal of the National Comprehensive Cancer Network 2022 cited by 76

  24. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

    Authors: Vina P. Nguyen, Katie M. Campbell, Theodore S. Nowicki, Nila Elumalai, Egmidio Medina, Ignacio Baselga-Carretero, Maggie L. DiNome, Helena R. Chang, Denise K. Oseguera, Antoni Ribas, John A. Glaspy - Cancer Research Communications 2023 cited by 19